Sarcoidosis – Pipeline Review, H2 2011
Sarcoidosis - Pipeline Review, H2 2011
Reference Code: GMDHC1578IDB
Publication Date: November 2011
Sarcoidosis – Pipeline Review, H2 2011 GMDHC1578IDB / Pub November 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Sarcoidosis – Pipeline Review, H2 2011
Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
List of Tables...................................................................................................................................................................................................... 3
List of Figures .................................................................................................................................................................................................... 4
Introduction .............................................................................................................................................................................................................. 5
Global Markets Direct Report Coverage ............................................................................................................................................................. 5
Sarcoidosis Overview ............................................................................................................................................................................................... 6
Therapeutics Development ....................................................................................................................................................................................... 7
An Overview of Pipeline Products for Sarcoidosis .............................................................................................................................................. 7
Sarcoidosis Therapeutics under Development by Companies .................................................................................................................................. 9
Sarcoidosis Therapeutics under Investigation by Universities/Institutes ...................................................................................................................10
Late Stage Products ................................................................................................................................................................................................11
Comparative Analysis .......................................................................................................................................................................................11
Mid Clinical Stage Products .....................................................................................................................................................................................12
Comparative Analysis .......................................................................................................................................................................................12
Discovery and Pre-Clinical Stage Products..............................................................................................................................................................13
Comparative Analysis .......................................................................................................................................................................................13
Sarcoidosis Therapeutics - Products under Development by Companies ................................................................................................................14
Sarcoidosis Therapeutics - Products under Investigation by Universities/Institutes ..................................................................................................15
Companies Involved in Sarcoidosis Therapeutics Development ..............................................................................................................................16
Johnson & Johnson...........................................................................................................................................................................................16
United Therapeutics Corporation .......................................................................................................................................................................16
Celgene Corporation .........................................................................................................................................................................................17
Mondobiotech Holding AG ................................................................................................................................................................................17
Centocor Ortho Biotech, Inc. .............................................................................................................................................................................18
Sarcoidosis - Therapeutics Assessment ..................................................................................................................................................................19
Assessment by Monotherapy Products .............................................................................................................................................................19
Assessment by Route of Administration ............................................................................................................................................................20
Assessment by Molecule Type ..........................................................................................................................................................................22
Drug Profiles ...........................................................................................................................................................................................................24
Aviptadil - Drug Profile.......................................................................................................................................................................................24
Product Description ....................................................................................................................................................................................24
Mechanism of Action...................................................................................................................................................................................24
R&D Progress .............................................................................................................................................................................................24
CC-10004 - Drug Profile ....................................................................................................................................................................................25
Product Description ....................................................................................................................................................................................25
Mechanism of Action...................................................................................................................................................................................25
R&D Progress .............................................................................................................................................................................................25
Stelara - Drug Profile.........................................................................................................................................................................................27
Product Description ....................................................................................................................................................................................27
Mechanism of Action...................................................................................................................................................................................27
R&D Progress .............................................................................................................................................................................................27
Rituximab - Drug Profile ....................................................................................................................................................................................29
Product Description ....................................................................................................................................................................................29
Mechanism of Action...................................................................................................................................................................................29
R&D Progress .............................................................................................................................................................................................29
Adalimumab - Drug Profile ................................................................................................................................................................................30
Product Description ....................................................................................................................................................................................30
Sarcoidosis – Pipeline Review, H2 2011 GMDHC1578IDB / Pub November 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)
Sarcoidosis – Pipeline Review, H2 2011
Mechanism of Action...................................................................................................................................................................................30
R&D Progress .............................................................................................................................................................................................30
Lipitor - Drug Profile .........................................................................................................................................................................